Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study

Remission is an ambitious but attainable goal for patients with asthma. The use of biological therapies can result in clinical remission. We aimed to evaluate clinical remission in real life among patients treated with mepolizumab and to detect characteristics of patients reaching remission. Patients included in the RELIGHT trial were evaluated at 12 and 24 months according to specific criteria. Remission definition:no exacerbation, no OCS, ACT score ≥20 and stable or improved lung function. 146 patients have been evaluated. Remission was achieved in 27.4% after 12 months of treatment and in 22% after 24 months. At 12 months, patients who achieved remission had a better baseline ACT score [17.0(14.0-19.0) vs 15.0(12.0-17.0), p=0.027], were using less oral corticosteroid as maintenance therapy at baseline (OCS) (35% vs 62.2%, p=0.004) and required lower baseline dose of OCS(mg/day) [5.0(5.0-10.0) vs 10.0(5.0-15.0), p=0.042] compared to those who did not. At 24 months patients who achieved remission were suffering less frequently from Gastroesophageal reflux disease (GERD) [10.3% vs 32%, p=0.031] and used lower doses of OCS at baseline (mg/day) [5.0(1.0-5.0) vs 10.0(5.0-15.0), p=<0.001] compared to those who did not achieve remission. 21 patients (52.5%) had sustained remission while 17 (42.5%) experienced relapse. Patients who experienced relapse suffered more frequently from GERD compared to those who had sustained remission 52.9% vs 4.8%, p=0.002 respectively. Patients who achieved remission had better asthma control and needed lower doses or no maintenance OCS at baseline. GERD seems to be an important factor affecting remission and relapse

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa1185
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study

Νikolaos Tzanakis, Maria Ntakoula, Κonstantinos Κatsoulis, Maria Kipourou et al.
Asthma and respiratory diseases
article

Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab:a post-hoc analysis of the 2-year RELIght study

Νikolaos Tzanakis, Maria Ntakoula, Κonstantinos Κatsoulis, Maria Kipourou, Evangelia Fouka, Panagiotis Lyberopoulos, Despoina Papakosta, Stylianos Vittorakis, Michael P. Makris, Panteleimon Avarlis, Anastasia Papaporfyriou, Εleftherios Ζervas, Katerina Markopoulou, Νikoletta Ρovina, K Porpodis, Mina Gaga, Petros Bakakos, Eleni Tzortzaki, Katerina Dimakou, Paschalis Steiropoulos, Stelios Loukides, Sevasti Ampelioti, Katerina M. Antoniou, Κonstantinos Κostikas, Μiltiadis Μarkatos, Sofia Koukidou, Κonstantinos Samitas, Konstantinos Glynos, Maria Kallieri, Εleni Gaki, Ιlias Papanikolaou, Marija Hadji-Mitrova, Spyros Papiris, Andriana Papaioannou
article en

Abstract

Remission is an ambitious but attainable goal for patients with asthma. The use of biological therapies can result in clinical remission. We aimed to evaluate clinical remission in real life among patients treated with mepolizumab and to detect characteristics of patients reaching remission. Patients included in the RELIGHT trial were evaluated at 12 and 24 months according to specific criteria. Remission definition:no exacerbation, no OCS, ACT score ≥20 and stable or improved lung function. 146 patients have been evaluated. Remission was achieved in 27.4% after 12 months of treatment and in 22% after 24 months. At 12 months, patients who achieved remission had a better baseline ACT score [17.0(14.0-19.0) vs 15.0(12.0-17.0), p=0.027], were using less oral corticosteroid as maintenance therapy at baseline (OCS) (35% vs 62.2%, p=0.004) and required lower baseline dose of OCS(mg/day) [5.0(5.0-10.0) vs 10.0(5.0-15.0), p=0.042] compared to those who did not. At 24 months patients who achieved remission were suffering less frequently from Gastroesophageal reflux disease (GERD) [10.3% vs 32%, p=0.031] and used lower doses of OCS at baseline (mg/day) [5.0(1.0-5.0) vs 10.0(5.0-15.0), p=<0.001] compared to those who did not achieve remission. 21 patients (52.5%) had sustained remission while 17 (42.5%) experienced relapse. Patients who experienced relapse suffered more frequently from GERD compared to those who had sustained remission 52.9% vs 4.8%, p=0.002 respectively. Patients who achieved remission had better asthma control and needed lower doses or no maintenance OCS at baseline. GERD seems to be an important factor affecting remission and relapse

Mediterranean Agronomic Institute of Chania (GR), University of Crete (GR), Democritus University of Thrace (GR), University of Ioannina (GR), National and Kapodistrian University of Athens (GR), Technological Educational Institute of Peloponnese (GR), Regional Energy Agency of Crete (GR), 424 General Military Hospital (GR), Corfu General Clinic (GR), Chania General Hospital ”St. George” (GR), Athens Medical Center (GR), University Hospital of Heraklion (GR), University General Hospital Attikon (GR), G. Papanikolaou General Hospital (GR), University Hospital of Alexandroupolis (GR), e-Trikala (Greece) (GR), Sotiria General Hospital (GR), Medical University of Vienna (AT)
Good health and well-being
Openalex Percentile: Top 72%
Asthma and respiratory diseases
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.